Magnetic resonance imaging of the adrenal gland.

The authors review their experience with magnetic resonance imaging (MRI) of the adrenal gland and discuss the appearance of adrenal diseases where MRI is clinically useful. A basic description of some of the newer pulse sequences is provided. Fat-suppressed MRI is advantageous because of reduction of cardiac and respiratory motion induced artifacts, accentuation of small differences in tissue contrast, and elimination of chemical shift artifacts. These advantages far outweigh the disadvantages of inhomogeneity of fat suppression and the fewer slices obtained per acquisition. Chemical shift imaging is used to differentiate benign from malignant adrenal diseases based on a gradient echo phase cycling technique. Detailed descriptions of MRI findings in adrenal pheochromocytomas, hemorrhage, cysts, adenomas, myelolipomas, and metastases are provided. Most pheochromocytomas appear markedly hyperintense to the liver on T2-weighted images. However, this appearance is not specific as adrenal metastases and adrenal adenomas may occasionally produce a similar appearance. In addition, pheochromocytomas may occasionally be isointense or hypointense to the liver on T2-weighted images. Differentiation of adrenal metastases from adrenal adenomas with MRI is problematic using signal intensity ratios (33% overlap) or T2 calculations. The future of discriminating between adrenal metastases and adenomas may rest with chemical shift MRI, which uses in- and out-of-phase gradient echo pulse sequences for differentiation. This approach relies on the fact that adrenal adenomas contain fat, while adrenal metastases do not. The reported accuracy of chemical shift imaging in differentiating between adrenal adenomas and adrenal metastases ranges from 96 to 100%. An algorithmic approach to differentiating benign from malignant adrenal diseases is presented that relies on an initial noncontrast CT with CT attenuation values obtained from the adrenal mass. If CT attenuation values are less than zero, the mass is characterized as benign. If the mass remains indeterminate after CT, chemical shift MR is performed. If the mass remains indeterminate after MR, biopsy is required.